Cart
sales@molnova.com
Disitamab vedotin
CAS No. 2136633-23-1
Disitamab vedotin( —— )
Catalog No. M35132 CAS No. 2136633-23-1
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 796 | In Stock |
|
| 10MG | 1102 | In Stock |
|
| 25MG | 1634 | In Stock |
|
| 50MG | 2158 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDisitamab vedotin
-
NoteResearch use only, not for human use.
-
Brief DescriptionDisitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.
-
DescriptionDisitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
-
In VitroThe antibody part was a humanized monoclonal antibody targeting HER2, the small molecule toxin was monomethyl auristatin E (MMAE), a synthetic antineoplastic agent. A protease cleavable linker covalently attached MMAE to the antibody.
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibody-Drug Conjugates (ADCs) | EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2136633-23-1
-
Formula WeightApproximately 144.15 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Deeks ED. Disitamab Vedotin: First Approval. Drugs. 2021;81(16):1929-1935.?
molnova catalog
related products
-
IDR-1
IDR-1 is an antimicrobial peptide that is active against Gram-positive and Gram-negative bacteria. IDR-1 counters infection by selective modulation of innate immunity without obvious toxicities. IDR-1 has anti-inflammatory and anti-infective properties, enhances the levels of monocyte chemokines, and attenuates pro-inflammatory cytokine release.
-
Geoside
Geoside is a natural compound isolated from stevia rebaudiana.
-
GRGDSP
GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
